Leclair N, Brugiolo M, Park S, Devoucoux M, Urbanski L, Angarola B
Nat Commun. 2025; 16(1):1670.
PMID: 39955311
PMC: 11829967.
DOI: 10.1038/s41467-025-56913-8.
Silvestri I, Manigrasso J, Andreani A, Brindani N, Mas C, Reiser J
Nat Commun. 2024; 15(1):4980.
PMID: 38898052
PMC: 11187226.
DOI: 10.1038/s41467-024-48697-0.
Bradley R, Anczukow O
Nat Rev Cancer. 2023; 23(3):135-155.
PMID: 36627445
PMC: 10132032.
DOI: 10.1038/s41568-022-00541-7.
Madanayake T, Welsh E, Darville L, Koomen J, Chalfant C, Haura E
Nucleic Acid Ther. 2022; 32(5):391-400.
PMID: 35861718
PMC: 9595651.
DOI: 10.1089/nat.2021.0101.
Bao G, Li T, Guan X, Yao Y, Liang J, Xiang Y
Front Oncol. 2022; 12:880478.
PMID: 35832557
PMC: 9271776.
DOI: 10.3389/fonc.2022.880478.
Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation.
Dou Z, Zhao D, Chen X, Xu C, Jin X, Zhang X
J Exp Clin Cancer Res. 2021; 40(1):194.
PMID: 34118966
PMC: 8196531.
DOI: 10.1186/s13046-021-02001-w.
Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
Cai Q, He B, Zhang P, Zhao Z, Peng X, Zhang Y
J Transl Med. 2020; 18(1):463.
PMID: 33287830
PMC: 7720605.
DOI: 10.1186/s12967-020-02635-y.
Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Wang L, Wang Y, Su B, Yu P, He J, Meng L
Sci Rep. 2020; 10(1):16504.
PMID: 33020551
PMC: 7536242.
DOI: 10.1038/s41598-020-73700-1.
A network-based computational framework to predict and differentiate functions for gene isoforms using exon-level expression data.
Wang D, Zou X, Au K
Methods. 2020; 189:54-64.
PMID: 32534132
PMC: 9628273.
DOI: 10.1016/j.ymeth.2020.06.005.
Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy.
Dzierlega K, Yokota T
Gene Ther. 2020; 27(9):407-416.
PMID: 32483212
DOI: 10.1038/s41434-020-0156-6.
Roles and mechanisms of alternative splicing in cancer - implications for care.
Bonnal S, Lopez-Oreja I, Valcarcel J
Nat Rev Clin Oncol. 2020; 17(8):457-474.
PMID: 32303702
DOI: 10.1038/s41571-020-0350-x.
RNA isoform screens uncover the essentiality and tumor-suppressor activity of ultraconserved poison exons.
Thomas J, Polaski J, Feng Q, De Neef E, Hoppe E, McSharry M
Nat Genet. 2020; 52(1):84-94.
PMID: 31911676
PMC: 6962552.
DOI: 10.1038/s41588-019-0555-z.
Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients.
De Fraipont F, Gazzeri S, Cho W, Eymin B
Front Genet. 2019; 10:390.
PMID: 31134126
PMC: 6514155.
DOI: 10.3389/fgene.2019.00390.
BCL-2 family isoforms in apoptosis and cancer.
Warren C, Wong-Brown M, Bowden N
Cell Death Dis. 2019; 10(3):177.
PMID: 30792387
PMC: 6384907.
DOI: 10.1038/s41419-019-1407-6.
Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski L, Leclair N, Anczukow O
Wiley Interdiscip Rev RNA. 2018; 9(4):e1476.
PMID: 29693319
PMC: 6002934.
DOI: 10.1002/wrna.1476.
Alternative Splicing as a Target for Cancer Treatment.
Martinez-Montiel N, Rosas-Murrieta N, Anaya Ruiz M, Monjaraz-Guzman E, Martinez-Contreras R
Int J Mol Sci. 2018; 19(2).
PMID: 29439487
PMC: 5855767.
DOI: 10.3390/ijms19020545.
Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.
Jyotsana N, Heuser M
Expert Opin Ther Targets. 2017; 22(2):107-121.
PMID: 29235382
PMC: 7116745.
DOI: 10.1080/14728222.2018.1417390.
Overcoming imatinib resistance conferred by the deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides.
Liu J, Bhadra M, Sinnakannu J, Yue W, Tan C, Rigo F
Oncotarget. 2017; 8(44):77567-77585.
PMID: 29100409
PMC: 5652800.
DOI: 10.18632/oncotarget.20658.
From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.
Tian N, Li J, Shi J, Sui G
Int J Mol Sci. 2017; 18(3).
PMID: 28257090
PMC: 5372486.
DOI: 10.3390/ijms18030191.
Melanoma Differentiation-associated Gene 7/IL-24 Exerts Cytotoxic Effects by Altering the Alternative Splicing of Bcl-x Pre-mRNA via the SRC/PKCδ Signaling Axis.
Shapiro B, Vu N, Shultz M, Shultz J, Mietla J, Gouda M
J Biol Chem. 2016; 291(41):21669-21681.
PMID: 27519412
PMC: 5076836.
DOI: 10.1074/jbc.M116.737569.